Mikael Dolsten, Pfizer CSO
FDA releases second Pfizer gene therapy from clinical hold, as hemophilia program gets OK to restart
The FDA has released a clinical hold on Pfizer and Sangamo’s hemophilia A gene therapy after ordering the companies to stop the trial last year …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
